bioAffinity (BIAF) 10-Q 2024 Q2 Quarterly report

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of bioAffinity Technologies, Inc., a Delaware Corporation (“Company”), for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (“Report”), each of the undersigned officers of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of such officer’s knowledge:

1)	the Report complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of June 30, 2024 (the last date of the period covered by the Report).

/s/ Maria Zannes

Maria Zannes

President and Chief Executive Officer

(Principal Executive Officer)

Date: August 14, 2024

/s/ Michael Dougherty

Michael Dougherty

Vice President and Chief Financial Officer

(Principal Financial Officer)

Date: August 14, 2024